clindamycin + vancomycin

Clindamycin + vancomycin is a combination of two antibiotics used primarily for the treatment of serious bacterial infections, particularly acute bacterial skin and skin-structure infections (ABSSSIs) often caused by methicillin-resistant Staphylococcus aureus (MRSA). Clindamycin is a lincosamide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit, thereby preventing peptide chain initiation. Vancomycin is a glycopeptide antibiotic that inhibits cell wall synthesis in susceptible bacteria by binding to D-Ala-D-Ala termini of cell wall precursor units. The combination may be used in clinical settings where broad-spectrum coverage against Gram-positive organisms, including MRSA and anaerobes, is required or when monotherapy has failed. Some studies suggest this combination can reduce hospital length of stay and readmission rates for patients with abscesses compared to monotherapy[1]. However, there are potential risks such as increased nephrotoxicity or neurotoxicity when these drugs are combined[2][4].